Tafenoquine treatment of Plasmodium vivax malaria: Suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

Malaria Journal

Volumn 15, Issue 1, 2016, Pages

  St Jean, Pamela L ^a   Xue, Zhengyu ^a   Carter, Nick ^b   Koh, Gavin C K W ^b   Duparc, Stephan ^c   Taylor, Maxine ^b   Beaumont, Claire ^b   Llanos Cuentas, Alejandro ^d   Rueangweerayut, Ronnatrai ^e   Krudsood, Srivicha ^f   Green, Justin A ^b   Rubio, Justin P ^g  

^a PAREXEL INTERNATIONAL   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Medicines for Malaria Venture   (Switzerland)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^e MAE SOT GENERAL HOSPITAL   (Thailand)

^f MAHIDOL UNIVERSITY   (Thailand)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CYP2D6; Efficacy; Pharmacogenetics; Pharmacokinetics; Plasmodium vivax malaria; Primaquine; Tafenoquine

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; CHLOROQUINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PLACEBO; PRIMAQUINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TAFENOQUINE; AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRAZIL; COLLISIONALLY ACTIVATED DISSOCIATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INDIA; INTENTION TO TREAT ANALYSIS; LIQUID CHROMATOGRAPHY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; PERU; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; THAILAND; CLINICAL TRIAL; MALARIA, VIVAX; METABOLISM; TREATMENT OUTCOME;

AMINOQUINOLINES; ANTIMALARIALS; CHLOROQUINE; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALARIA, VIVAX; PRIMAQUINE; TREATMENT OUTCOME;

EID: 84959143782     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-016-1145-5     Document Type: Article

References (17)

1. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: Neglected and not benign. Am J Trop Med Hyg. 2007;77(6 Suppl):79-87.
2. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): A multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049-58.
3. Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar J. 2012;11:259.
4. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J. 2013;12:212.
5. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369:1381-2.
6. Potter BM, Xie LH, Vuong CT, Zhang J, Zhang P, Duan D, et al. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics. Antimicrob Agents Chemother. 2015;59:2380-7.
7. Ingram RJH, Crenna-Darusallam C, Soebianto S, Noviyanti R, Baird JK. The clinical and public health problem of relapse despite primaquine therapy: Case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malar J. 2014;13:488.
8. Marcsisin SR, Sousa JC, Reichard GA, Caridha D, Zeng Q, Roncal N, et al. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: Implications for the 8-aminoquinoline class of anti-malarial compounds. Malar J. 2014;13:2.
9. Vuong C, Xie LH, Potter BMJ, Zhang J, Zhang P, Duan D, et al. Differential CYP 2D6 metabolism alters tafenoquine pharmacokinetics. Antimicrob Agents Chemother. 2015;59:3864-9.
10. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48:689-723.
11. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin Pharmacokinet. 2009;48:761-804.
12. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: Translating genotype information into a quantitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234-42.
13. Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, et al. The AmpliChip CYP450 test: Cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009;9:34-41.
14. Tenero D, Green JA, Goyal N. Exposure-response analyses for tafenoquine after administration to patients with Plasmodium vivax malaria. Antimicrob Agents Chemother. 2015;59:6188-94.
15. Di L, Trapa P, Obach RS, Atkinson K, Bi YA, Wolford AC, et al. A novel relay method for determining low-clearance values. Drug Metab Dispos. 2012;40:1860-5.
16. Edgcomb JH, Arnold J, Yount EH Jr, Alving AS, Eichelberger L, Jeffery GM, et al. Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. J Natl Malar Soc. 1950;9:285-92.
17. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17:93-101.